Providing a broad portfolio
Molecular Imaging in Precision Health
Building Expertise
Pioneering Research
Molecular Imaging Insights
You can count on a broad portfolio of products and solutions
Products
We continue to put the future first, globally
By bringing clinically relevant applications to the market, improving access to nuclear medicine and enhancing outcomes for patients.
Significant R&D investment. Enhancing diagnostic accuracy to enable you to improve patient outcomes
$25M
R&D investment in 2018
16
innovative products launched in 15 years
198
patent applications in 10 years
Enhancing clinical trials. New diagnostic options for clinicians and their patients
35
GE sponsored clinical trials
69
external clinical studies
Continued focus on development of new tracers
Strong pharma partnership. Advance in companion diagnostics for personalised treatment
4200+
doses delivered for clinical trials in 2018 worldwide
15+
contracts over the last 5 years to study innovative drugs
Contact Us
DaTSCAN, Rapiscan and SeHCAT are trademarks of GE.
JB01438UK | August 2021